E3 PreliminaryPreliminaryPEM unclearPeer-reviewedMachine draft
[A case of chronic fatigue syndrome who showed a beneficial effect by intravenous administration of magnesium sulphate].
Takahashi, H, Imai, K, Katanuma, A et al. · Arerugi = [Allergy] · 1992
Quick Summary
This case study describes a 29-year-old woman with ME/CFS who had severe fatigue, fever, swollen lymph nodes, and muscle pain that didn't improve with standard treatments. When doctors gave her intravenous magnesium sulphate once a week for about 6 weeks, her extreme tiredness improved and she was able to do more daily activities, eventually leaving the hospital.
Why It Matters
Magnesium deficiency has been hypothesized in ME/CFS pathophysiology, and this early case report suggests intravenous magnesium may benefit some patients with severe fatigue unresponsive to conventional treatment. The case also documents immune abnormalities commonly observed in ME/CFS, providing clinical context for potential biological mechanisms.
Observed Findings
- Immune abnormalities including low NK cell activity, reduced ADCC activity, elevated serum IgE, and positive RAST scores
- Elevated antinuclear antibody (2520x) despite collagen disease being ruled out
- Clinical symptom improvement and reduced fatigability reported after 6 weeks of weekly intravenous magnesium sulphate administration
- Failed response to non-steroidal anti-inflammatory drugs, minor tranquilizers, and antidepressants prior to magnesium treatment
Inferred Conclusions
- Intravenous magnesium sulphate may have therapeutic benefit in ME/CFS patients with severe, treatment-resistant fatigue
- Magnesium administration may improve functional capacity and daily activity tolerance in ME/CFS
- Immunomodulatory mechanisms involving NK cells and IgE may be relevant to ME/CFS pathophysiology
Remaining Questions
- Would intravenous magnesium be effective in other ME/CFS patients, or was this a unique response?
- What is the optimal dosing, frequency, and duration of magnesium sulphate treatment?
- Which patient characteristics predict a favorable response to magnesium therapy?
What This Study Does Not Prove
This is a single case report with no control group, placebo comparison, or blinded assessment, so it cannot prove magnesium sulphate is effective for ME/CFS generally or establish causation. The concurrent improvement could reflect natural disease fluctuation, placebo effect, or regression to the mean rather than a specific treatment benefit.
Tags
Symptom:Unrefreshing SleepPainFatigueTemperature Dysregulation
Biomarker:Blood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedNo ControlsSmall SampleExploratory Only
Metadata
- PMID
- 1492795
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →